Safety of inactivated influenza vaccines references

  1. Medsafe. Data sheet – Afluria Quad/Afluria Quad Junior [Internet]. Wellington: New Zealand Medicines and Medical Devices Safety Authority; forthcoming 2021.
  2. Medsafe. Data sheet – Fluad Quad [Internet]. Wellington: New Zealand Medicines and Medical Devices Safety Authority; 2020 [updated 2020 December 11; cited 2021 February 3]. Available from:
  3. Schultze V, D’Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59™ adjuvant. Vaccine. 2008;26(26):3209-22.
  4. Feng S, Fowlkes AL, Steffens A, Finelli L, Cowling BJ. Assessment of virus interference in a test-negative Study of influenza vaccine effectiveness. Epidemiology. 2017;28(4):514-24.
  5. Skowronski DM, Zou M, Clarke Q, Chambers C, Dickinson JA, Sabaiduc S, et al. Influenza vaccine does not increase the risk of coronavirus or other noninfluenza respiratory viruses: Retrospective analysis from Canada, 2010–2011 to 2016–2017. Clin Infect Dis. 2020;71(16):2285-8.
  6. Moa AM, Chughtai AA, Muscatello DJ, Turner RM, MacIntyre CR. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials. Vaccine. 2016;34(35):4092-102.
  7. Treanor JT, Albano FR, Sawlwin DC, Graves Jones A, Airey J, Formica N, et al. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study. Vaccine. 2017;35(15):1856-64.
  8. Airey J, Albano FR, Sawlwin DC, Jones AG, Formica N, Matassa V, et al. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study. Vaccine. 2017;35(20):2745-52.
  9. Statler VA, Albano FR, Airey J, Sawlwin DC, Graves Jones A, Matassa V, et al. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6–59 months of age: A phase 3, randomized, noninferiority study. Vaccine. 2019;37(2):343-51.
  10. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database. Vaccine. 2009;27(49):6959-65.
  11. Frey SE, Reyes MRA-DL, Reynales H, Bermal NN, Nicolay U, Narasimhan V, et al. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine. 2014;32(39):5027-34.
  12. Cowling BJ, Thompson MG, Ng TWY, Fang VJ, Perera RAPM, Leung NHL, et al. Comparative reactogenicity of enhanced influenza vaccines in older adults. J Infect Dis. 2020;222(8):1383-91.
  13. Nicolay U, Heijnen E, Nacci P, Patriarca PA, Leav B. Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience. Int J Infect Dis. 2019;85:S1-S9.
  14. McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016;137(3):868-78.
  15. Bresee J, Fry A, Sambhara S, Cos N. Inactivated influenza vaccines. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines. 7th ed. Philadelphia: Elsevier; 2018. p. 456-88.
  16. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36-44.
  17. Sawlwin DC, Graves Jones A, Albano FR. Modification of the vaccine manufacturing process improves the pyrogenicity profile of inactivated influenza vaccines in young children. Vaccine. 2019;37(18):2447-54.
  18. McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barre syndrome worldwide. Neuroepidemiology. 2009;32(2):150-63.
  19. Schonberger L, Bregman D, Sullivan-Bolyai J, Keenlyside R, Ziegler D, Retailliau H, et al. Guillain-Barre syndrome following vaccination in the National Influenza Program, United States, 1976–1977. Am J Epidemiol. 1979;110(2):105-23.
  20. Arias LHM, Sanz R, Sainz M, Treceno C, Carvajal A. Guillain-Barre syndrome and influenza vaccines: A meta-analysis. Vaccine. 2015;33(31):3773-8.
  21. Iqbal S, Li R, Gargiullo P, Vellozzi C. Relationship between Guillain-Barre syndrome, influenza-related hospitalizations, and influenza vaccine coverage. Vaccine. 2015;33(17):2045-9.
  22. Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenza like illness using the United Kingdom General Practice Research Database. Am J Epidemiol. 2009;169(3):382-8.
  23. Poland GA, Poland CM, Howe CL. Influenza vaccine and Guillain-Barre syndrome: Making informed decisions. Lancet. 2013;381(9876):1437-9.
  24. Sadleir LG, Scheffer IE. Febrile seizures. BMJ. 2007;334(7588):307-11.
  25. Stockwell MS, Broder K, LaRussa P, et al. Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine. JAMA Pediatrics. 2014;168(3):211-9.